dm+d

Unassigned

New Medicines

Prevention of bleeding episodes in haemophilia A and B

Information

New molecular entity
Novo Nordisk
Novo Nordisk Biopharm

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

High-affinity, humanised, recombinant monoclonal antibody that inhibits TFPI (tissue factor pathway inhibitor), allowing FVIIa:tissue factor complex to generate more activated factor X. Given by daily injection.
Haemophilia A affects 1:4,000 to 1:5,000 live male births worldwide, Haemophilia B is rarer [8].
Prevention of bleeding episodes in haemophilia A and B
Subcutaneous injection

Further information

Yes

Evidence based evaluations